Literature DB >> 20135752

Might platelet-leucocyte complexes be playing a role in major vascular involvement of Behçet's disease? A comparative study.

Gülsüm Emel Pamuk1, Omer Nuri Pamuk, Hüseyin Orüm, Muzaffer Demir, Burhan Turgut, Necati Cakir.   

Abstract

We determined platelet-leucocyte complexes, which play roles in the thrombosis-inflammation relationship, in Behçet's disease patients with and without major vascular involvement (MVI) and in healthy controls. We included 36 Behçet's disease patients (22 male, 14 female, mean age: 34.4 +/- 8.3 years) and 20 healthy individuals (14 male, six female, mean age: 31.8 +/- 4.4 years). Whole blood count, CRP and ESR were determined in both groups. Clinical data about the patients were obtained from medical charts. Individuals with hypertension, diabetes, coronary artery disease, and smokers were excluded. Behçet's disease patients with MVI were taken as a separate group (8 male, 5 female, mean age: 37 +/- 8 years). MVI was defined as the presence of pulmonary arterial aneurysm, deep venous thrombosis, vena cava inferior or superior thrombosis, or venous sinus thrombosis. Flow cytometry was used to determine platelet-monocyte complexes (PMC), platelet-neutrophil complexes (PNC), basal and adenosine diphosphate (ADP)-stimulated platelet CD62P expression. Behçet's disease patients with MVI had significantly higher PNC than Behçet's disease patients without MVI and healthy controls (P values = 0.01). PMC levels in Behçet's disease patients with MVI were significantly higher than in healthy controls (P = 0.01). The groups were similar in basal and ADP-stimulated platelet CD62P expression (P values >0.05). Basal and ADP-stimulated CD62P expression, PMC and PNC were not significantly different between active Behçet's disease versus inactive Behçet's disease patients. The evaluated parameters were similar in Behçet's disease patients with and without uveitis, and pathergy-positive and pathergy-negative groups. Our results might suggest that the formation of PMC and PNC might play a role in thrombosis and MVI of Behçet's disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20135752     DOI: 10.1097/mbc.0b013e328330bdc4

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  3 in total

1.  Behcet's Disease: New Concepts in Cardiovascular Involvements and Future Direction for Treatment.

Authors:  M B Owlia; G Mehrpoor
Journal:  ISRN Pharmacol       Date:  2012-03-08

2.  Correlation of clinical signs and symptoms of Behçet's disease with mean platelet volume (MPV) and red cell distribution width (RDW).

Authors:  Maryam Masoumi; Soraya Shadmanfar; Fereydoun Davatchi; Farhad Shahram; Massoomeh Akhlagi; Tahereh Faezi; Hoda Kavosi; Soroush Moradi; Javad Balasi
Journal:  Orphanet J Rare Dis       Date:  2020-10-21       Impact factor: 4.123

3.  Comprehensive analysis of immunoglobulin and clinical variables identifies functional linkages and diagnostic indicators associated with Behcet's disease patients receiving immunomodulatory treatment.

Authors:  Linlin Cheng; Yang Li; Ziyan Wu; Liubing Li; Chenxi Liu; Jianhua Liu; Jiayu Dai; Wenjie Zheng; Fengchun Zhang; Liujun Tang; Xiaobo Yu; Yongzhe Li
Journal:  BMC Immunol       Date:  2021-02-22       Impact factor: 3.615

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.